Collective Audience, Inc. (the "Company"), a Nevada corporation, has announced the offering of 3,638,442 shares of Common Stock and 1,697,678 shares of Common Stock underlying warrants by selling securityholders. The shares and warrants were initially issued to various parties, including the Company's sponsor, Abri Ventures I, LLC, and Chardan Capital Markets, LLC, as part of private transactions and are now being registered for resale. The selling securityholders may sell their shares at market prices or through negotiated transactions, and the Company will not receive any proceeds from the sale. The offering allows selling securityholders to sell their shares and warrants, which may include shares issued as part of a business combination with Abri SPAC I, Inc., a special purpose acquisition company...Show More

Collective Audience, Inc. (the "Company"), a Nevada corporation, has announced the offering of 3,638,442 shares of Common Stock and 1,697,678 shares of Common Stock underlying warrants by selling securityholders. The shares and warrants were initially issued to various parties, including the Company's sponsor, Abri Ventures I, LLC, and Chardan Capital Markets, LLC, as part of private transactions and are now being registered for resale. The selling securityholders may sell their shares at market prices or through negotiated transactions, and the Company will not receive any proceeds from the sale. The offering allows selling securityholders to sell their shares and warrants, which may include shares issued as part of a business combination with Abri SPAC I, Inc., a special purpose acquisition company ("SPAC"). The Company, which operates through its subsidiary DLQ, Inc., focuses on consumer data management, lead generation, and digital marketing. The shares of Common Stock are listed on the Nasdaq Global Market under the symbol "CAUD," while the warrants were previously listed under the symbol "CAUDW" until November 3, 2023, and are currently unlisted. The offering is subject to customary closing conditions and regulatory approvals.